CAMBRIDGE, Mass. & PARIS--(BUSINESS WIRE)--EOS imaging (NYSE Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced that the EOS® imaging System is now installed in five of the top 10 ranking U.S. hospitals for orthopedic care.
“After Barnes-Jewish Hospital, NYU Langone Medical Center, Massachusetts General Hospital and earlier this month Hospital for Special Surgery, the new adoption of EOS by the Mayo Clinic marks the growing success of our unique technology as the standard of care in orthopedic imaging.”
Marie Meynadier, CEO of EOS imaging, said, “After Barnes-Jewish Hospital, NYU Langone Medical Center, Massachusetts General Hospital and earlier this month Hospital for Special Surgery, the new adoption of EOS by the Mayo Clinic marks the growing success of our unique technology as the standard of care in orthopedic imaging.”
EOS is the only low-dose, 2D/3D orthopedic imaging system to provide full-body scans of patients in a natural standing or seated position. It is based on Nobel Prize-winning technology that enables it to capture high-quality images while delivering a radiation dose that is nine times lower than that of computed radiography X-ray1 and 20 times lower than basic CT scans2. The system also automatically calculates a broad range of clinical parameters for more informed diagnosis and treatment of orthopedic conditions.
These medical centers have been named among the top 10 hospitals for orthopedics in the country by U.S. News & World Report. Mayo Clinic, which had the latest EOS installation, has been named the No. 2 hospital for orthopedics in the country by the U.S. News & World Report, as well as the No. 3 hospital overall. All are incorporating the technology into regular orthopedic practice, where it is used for both clinical research and patient care.
For more information on EOS and its technology, visit www.eos-imaging.com.
About EOS imaging:
The EOS imaging group designs, develops and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Group has obtained authorization to market the system in 30 countries, including the United States (FDA), Canada, Australia and the European Union (EU). Thanks to an installed base of 53 sites and more than 250,000 imaging sessions, EOS® benefits from worldwide recognition and established credibility within the medical community. The Group currently employs 64 people, including an R&D team of 21 engineers, and recorded consolidated revenue of €6.94 million in 2011. The Group's head office is based in Paris, with a subsidiary in the United States in Cambridge (Massachusetts), as well as in Montreal (Canada) and Germany. For further information, please go to: www.eos-pimaging.com.
EOS imaging is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
Next press release: 2012 annual sales on 21 January 2013 (after market).
1 S. Parent et al. “Diagnostic imaging of spinal
deformities: Reducing patients radiation dose with a new slot-scanning
x-ray imager.” Spine. April 2010, 35 (9): 989
2 Rapport DRPH/SER n°2010-08 – IRSN (Institut de Radioprotection et de Sûreté Nucléaire)